Dutch Battery Startup LionVolt Closes €4 Million Seed Round Led by Innovation Industries
18.11.2021 10:10:00 EET | Business Wire | Press release
European battery start-up LionVolt announced today it has successfully closed a seed round of €4 million, bringing its total funding this year to more than €5 million.
The round was led by deep tech venture capital firm Innovation Industries and joined by Brabant-focused startup fund Brabantse Ontwikkelingsmaatschappij (Brabant Development Agency, BOM) and renowned investor Sake Bosch. LionVolt spun off last year from TNO at Holst Centre, building on six years of research and development of its innovative battery design.
The funding will support the company’s development of a solid-state lithium-ion battery that is more efficient and sustainable than any lithium-ion battery available on the market today. LionVolt’s cutting edge design delivers higher energy density, faster charging, and a longer lifespan - leading to fewer batteries used (and disposed of) over time. The LionVolt battery will power technology in several industries, including wearable devices, electric vehicles (EVs) and aviation.
"The battery industry requires a bold new approach to meet evolving needs in terms of cost, performance, safety and sustainability. We are pioneering that solution while building a strong ecosystem to support this innovation," said LionVolt CEO Karl McGoldrick. "The support of TNO and our investors will not only bring our R&D to its next stage but will further establish the Netherlands as a hub of Climate Technologies."
“This is an exciting milestone for LionVolt,” remarked LionVolt CTO and co-founder Dr Sandeep Unnikrishnan. “We are creating batteries that will transform the energy sector in terms of safety, energy density and performance. LionVolt is proud to continue its game-changing innovation from the Brabant region.”
“LionVolt’s new technology will provide consumers with better, longer-lasting batteries while also contributing to the adoption of exciting technologies like wearables and electric cars,” added Nard Sintenie, partner at Innovation Industries. “We are proud to work with LionVolt and support their mission to revolutionise the battery industry.”
“LionVolt is a strong example of the innovation occurring in the Brabant region of the Netherlands,” added Jurgen van Eck of the Brabant Development Agency (BOM). “The BOM invests in LionVolt because the company has enormous potential. Almost 80 percent of the supply chain the company needs to build a production line can be sourced locally. LionVolt could be one of the next big OEM’s in the Brainport region.”
Earlier this year LionVolt already raised a €1.25 million pre-seed round from TNO, deep tech venture capital firm Innovation Industries, impact fund Goeie Grutten, and Brabant-focused early stage investment Brabant Startup Fonds (BSF) and the Brabantse Ontwikkelingsmaatschappij (BOM).
About LionVolt
Backed by more than seven years of R&D at the TNO Holst Centre, LionVolt is developing a 3D, solid-state, lithium metal battery. Its mission is to introduce next-gen batteries that are energy-dense, fast charging, safe, and efficient while being more environmentally friendly than traditional lithium-ion batteries. LionVolt’s design is 100% safe, weighs 50% less and provides 200% improved performance compared to the most advanced lithium-ion batteries available today. To learn more, visit www.lionvolt.com.
About Innovation Industries
Innovation Industries is a leading investment firm and strategic innovation partner for sustainable impact, leveraging deep industry expertise and rich deal flow in areas like semicon, photonics, robotics, medtech, agri&food tech, and mechatronics. We facilitate and drive the creation and broad adoption of sustainable deep-tech solutions and translate these opportunities into value for our investors and other stakeholders. We invest across all stages of development and our typical investment size ranges from €5M-€30M (cumulative). For more information on Innovation Industries, see: www.innovationindustries.com
About Brabantse Ontwikkelingsmaatschappij (BOM)
The Brabant Development Agency (BOM) works with entrepreneurs to create a future-proof Brabant economy. BOM shares knowledge, develops networks, and provides capital to innovative Brabant companies and sustainable energy projects. It also encourages forward-looking international companies to settle in Brabant and assist companies already based in Brabant to extend their reach abroad. BOM works to further economic growth, increase employment opportunities, present solutions to social issues, and secure a leading role for Brabant on the world stage. Over the last four years, BOM has worked with over 600 companies to catalyze change and achieve impact. For more information, please visit www.bom.nl
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006209/en/
Contact information
Rachel Pipan
info@lionvolt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom